<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739113</url>
  </required_header>
  <id_info>
    <org_study_id>104-7758C</org_study_id>
    <nct_id>NCT02739113</nct_id>
  </id_info>
  <brief_title>Cultivated Autologous Oral Mucosal Epithelial Transplantation for the Treatment of Ocular Surface Diseases</brief_title>
  <official_title>Cultivated Autologous Oral Mucosal Epithelial Transplantation for the Treatment of Ocular Surface Diseases: Phase Ib Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Earlier protocol for cultivated oral mucosal epithelial transplantation (COMET) requires
      trypsin/EDTA to isolate epithelial cells from tissue, and uses murine 3T3 cells as feeder
      cells, which results in biosafety concern. This study uses collagenase instead of
      trypsin/EDTA to isolate epithelial cells, and does not use 3T3 cells co-culture, so as to
      make an animal ingredient-free cell culture product. The purpose of the study is to evaluate
      the feasibility of the new protocol of COMET in clinical use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When corneal epithelial stem cells are destroyed by severe trauma such as burn or autoimmune
      diseases, poor regeneration of corneal epithelium, persistent inflammatory reaction,
      neovascular ingrowth, and conjunctivalization may ensue, and seriously reduce the vision. In
      treating the diseased eye, when the other eye is healthy, limbal tissue containing corneal
      epithelial stem cells can be harvested for direct tissue transplantation, or ex vivo
      cultivation and expansion for several days before transplantation.

      For patients with bilaterally damaged eyes, rejection rate in non-HLA matched allograft
      limbal stem cell transplantation is very high, in addition, adverse reaction to long-term
      immunosuppressive therapy may be life-threatening. Therefore, in 2004 Japanese researchers
      first proposed a novel technique to treat ocular surface diseases using cultivated autologous
      oral mucosal epithelial transplantation (COMET). From 2006 to 2009, investigators have also
      conducted a Phase I clinical trial approved by Taiwan FDA. In that Phase I trial,
      investigators have demonstrated efficacy of such cell therapy in promoting wound healing in
      patients with severe ocular surface burns (Ma DHK et al. Eye 2009; 23: 1442- 1450).
      Investigators have also identify long-term persistence of transplanted oral mucosal
      epithelial cells in the cornea (Chen HCJ et al. Invest Ophthalmol Vis Sci 2009;50:4660-4668),
      justifying this innovative surgical procedure as an effective alternative treatment modality.

      However, in previous protocol, animal products such as fetal calf serum and 3T3 cell culture
      were used, raising the biosafety concern. For this, recently investigators have developed an
      animal ingredient-free cell culture protocol, and our protocol can meet the GTP standards,
      and has obtained the accreditation by Taiwan FDA and affiliated institutes. Therefore, the
      focus of current Phase Ib trial is to confirm the feasibility of following items:

        1. To produce cell culture product not containing animal ingredient, so as to avoid
           zoonoses. The oral mucosal epithelial cells thus cultured are used for treating ocular
           surface diseases with limbal stem cell deficiency.

        2. To reduce recurrence of corneal neovascularization after COMET, Bevacizumab (Avastin) is
           injected locally, so as to improve corneal transparency and visual acuity.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Re-epithelialization of cornea</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regression of corneal neovascularization: Final averaged length of corneal blood vessels less than 35% total corneal area occupied by blood vessels.</measure>
    <time_frame>6-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of best corrected visual acuity: At least 2 lines of improvement.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in corneal clarity (slit lamp examination): Improvement at least one grade.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Limbal Stem Cell Deficiency</condition>
  <arm_group>
    <arm_group_label>Cultivated oral mucosal epithelial cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cultivated oral mucosal epithelial cell transplantation (COMET) : To treat severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cultivated oral mucosal epithelial cell</intervention_name>
    <description>Cell therapy for treating severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cells.</description>
    <arm_group_label>Cultivated oral mucosal epithelial cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe corneal epithelial deficiency

          -  Having favorable prognosis potential

          -  Normal of the intraocular pressure

          -  Normal of the light perception for the optic nerve

          -  No retinal diseases for the inflicted eyes

          -  No severe dry eye

        Exclusion Criteria:

          -  Having unfavorable prognosis potential

          -  Severe systemic disorders

          -  Unable to use daily vision

          -  Mentally retarded to execute permit on surgery

          -  Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hui-Kang Ma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Chen HC, Chen HL, Lai JY, Chen CC, Tsai YJ, Kuo MT, Chu PH, Sun CC, Chen JK, Ma DH. Persistence of transplanted oral mucosal epithelial cells in human cornea. Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4660-8. doi: 10.1167/iovs.09-3377. Epub 2009 May 20.</citation>
    <PMID>19458337</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen HC, Yeh LK, Tsai YJ, Lai CH, Chen CC, Lai JY, Sun CC, Chang G, Hwang TL, Chen JK, Ma DH. Expression of angiogenesis-related factors in human corneas after cultivated oral mucosal epithelial transplantation. Invest Ophthalmol Vis Sci. 2012 Aug 17;53(9):5615-23. doi: 10.1167/iovs.11-9293.</citation>
    <PMID>22850415</PMID>
  </results_reference>
  <results_reference>
    <citation>Inatomi T, Nakamura T, Koizumi N, Sotozono C, Yokoi N, Kinoshita S. Midterm results on ocular surface reconstruction using cultivated autologous oral mucosal epithelial transplantation. Am J Ophthalmol. 2006 Feb;141(2):267-275.</citation>
    <PMID>16458679</PMID>
  </results_reference>
  <results_reference>
    <citation>Inatomi T, Nakamura T, Kojyo M, Koizumi N, Sotozono C, Kinoshita S. Ocular surface reconstruction with combination of cultivated autologous oral mucosal epithelial transplantation and penetrating keratoplasty. Am J Ophthalmol. 2006 Nov;142(5):757-64. Epub 2006 Sep 20.</citation>
    <PMID>16989763</PMID>
  </results_reference>
  <results_reference>
    <citation>Li W, Sabater AL, Chen YT, Hayashida Y, Chen SY, He H, Tseng SC. A novel method of isolation, preservation, and expansion of human corneal endothelial cells. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):614-20.</citation>
    <PMID>17251457</PMID>
  </results_reference>
  <results_reference>
    <citation>Ma DH, Kuo MT, Tsai YJ, Chen HC, Chen XL, Wang SF, Li L, Hsiao CH, Lin KK. Transplantation of cultivated oral mucosal epithelial cells for severe corneal burn. Eye (Lond). 2009 Jun;23(6):1442-50. doi: 10.1038/eye.2009.60. Epub 2009 Apr 17.</citation>
    <PMID>19373264</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakamura T, Inatomi T, Sotozono C, Amemiya T, Kanamura N, Kinoshita S. Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. Br J Ophthalmol. 2004 Oct;88(10):1280-4.</citation>
    <PMID>15377551</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakamura T, Takeda K, Inatomi T, Sotozono C, Kinoshita S. Long-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders. Br J Ophthalmol. 2011 Jul;95(7):942-6. doi: 10.1136/bjo.2010.188714. Epub 2010 Nov 19.</citation>
    <PMID>21097786</PMID>
  </results_reference>
  <results_reference>
    <citation>Petsoglou C, Balaggan KS, Dart JK, Bunce C, Xing W, Ali RR, Tuft SJ. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol. 2013 Jan;97(1):28-32. doi: 10.1136/bjophthalmol-2012-302137. Epub 2012 Oct 20.</citation>
    <PMID>23087419</PMID>
  </results_reference>
  <results_reference>
    <citation>Satake Y, Higa K, Tsubota K, Shimazaki J. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. Ophthalmology. 2011 Aug;118(8):1524-30. doi: 10.1016/j.ophtha.2011.01.039. Epub 2011 May 14.</citation>
    <PMID>21571372</PMID>
  </results_reference>
  <results_reference>
    <citation>Takeda K, Nakamura T, Inatomi T, Sotozono C, Watanabe A, Kinoshita S. Ocular surface reconstruction using the combination of autologous cultivated oral mucosal epithelial transplantation and eyelid surgery for severe ocular surface disease. Am J Ophthalmol. 2011 Aug;152(2):195-201.e1. doi: 10.1016/j.ajo.2011.01.046. Epub 2011 Jun 8.</citation>
    <PMID>21652025</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>David Hui-Kang Ma</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>OMECs</keyword>
  <keyword>Cornea</keyword>
  <keyword>Amniotic membrane</keyword>
  <keyword>Collagenase</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 23, 2016</submitted>
    <returned>January 18, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

